Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
Katharina Pomej,1,2,* Lorenz Balcar,1– 3,* Bernhard Scheiner,1– 4 Georg Semmler,1,3 Tobias Meischl,1,2 Mattias Mandorfer,1,3,4 Thomas Reiberger,1,3– 5 Christian Müller,1,2 Michael Trauner,1,4 Matthias Pinter1,2,4 1Division of Gastroenterology and Hepatology, Department of Internal Me...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/34e445ecb8884eeb86cb8d444efa3051 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:34e445ecb8884eeb86cb8d444efa3051 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:34e445ecb8884eeb86cb8d444efa30512021-11-30T18:50:37ZAntibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib2253-5969https://doaj.org/article/34e445ecb8884eeb86cb8d444efa30512021-11-01T00:00:00Zhttps://www.dovepress.com/antibiotic-therapy-is-associated-with-worse-outcome-in-patients-with-h-peer-reviewed-fulltext-article-JHChttps://doaj.org/toc/2253-5969Katharina Pomej,1,2,* Lorenz Balcar,1– 3,* Bernhard Scheiner,1– 4 Georg Semmler,1,3 Tobias Meischl,1,2 Mattias Mandorfer,1,3,4 Thomas Reiberger,1,3– 5 Christian Müller,1,2 Michael Trauner,1,4 Matthias Pinter1,2,4 1Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; 2Liver Cancer (HCC) Study Group Vienna, Medical University of Vienna, Vienna, Austria; 3Vienna Hepatic Hemodynamic Laboratory, Medical University of Vienna, Vienna, Austria; 4Rare Liver Disease (RALID) Centre of the ERN RARE-LIVER, Medical University of Vienna, Vienna, Austria; 5Christian Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria*These authors contributed equally to this workCorrespondence: Matthias PinterDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, AustriaTel +43 1 40400 47440Fax +43 1 40400 47350Email matthias.pinter@meduniwien.ac.atBackground: Antibiotic treatment (ABT) affects the outcome of cancer patients treated with immune checkpoint inhibitors (ICIs) and chemotherapy, possibly by altering the gut microbiome. We investigated the impact of ABT on overall survival (OS) and progression-free survival (PFS) in patients with advanced HCC treated with sorafenib.Methods: HCC patients treated with sorafenib between 05/2006 and 03/2020 at the Medical University of Vienna were retrospectively analyzed. ABT was defined as antibiotic use within 30 days prior to or after sorafenib initiation.Results: Of 206 patients, the majority was male (n=171, 83%) with a mean age of 66± 9.6 years. Half of patients (n=94, 46%) had impaired liver function (Child-Pugh stage B). Median time of follow-up was 10.8 (95% CI: 9.2– 12.3) months. ABT was administered in 23 (11%) patients due to different types of proven or clinically suspected bacterial infections (n=17, 74%) and hepatic encephalopathy (n=6, 26%). The median duration of ABT was 14 (IQR: 12– 30) days. Penicillin (n=13, 57%), followed by rifaximin (n=6, 26%), fluoroquinolones (n=3, 13%), and cephalosporins (n=1, 4%), was administered in the ABT group. The ABT group had a significantly shorter median OS (4.7 (95% CI: 3.2– 6.1) months vs 11.4 (95% CI: 9.9– 12.9) months, p=0.012), which was confirmed in multivariable analysis (HR: 1.91 (95% CI: 1.1– 3.2), p=0.014). Similarly, PFS trended to be shorter in the ABT group (3.5 (95% CI: 1.6– 5.4) months vs 4.8 (95% CI: 3.9– 5.7) months, p=0.099). None of the 10 patients with complete or partial response was found in the ABT group.Conclusion: ABT was independently associated with worse outcomes in sorafenib-treated HCC patients. Prospective studies are needed to elucidate the underlying mechanism.Keywords: antibiotics, hepatocellular carcinoma, sorafenib, targeted therapyPomej KBalcar LScheiner BSemmler GMeischl TMandorfer MReiberger TMüller CTrauner MPinter MDove Medical Pressarticleantibioticshepatocellular carcinomasorafenibtargeted therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of Hepatocellular Carcinoma, Vol Volume 8, Pp 1485-1493 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
antibiotics hepatocellular carcinoma sorafenib targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
antibiotics hepatocellular carcinoma sorafenib targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Pomej K Balcar L Scheiner B Semmler G Meischl T Mandorfer M Reiberger T Müller C Trauner M Pinter M Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib |
| description |
Katharina Pomej,1,2,* Lorenz Balcar,1– 3,* Bernhard Scheiner,1– 4 Georg Semmler,1,3 Tobias Meischl,1,2 Mattias Mandorfer,1,3,4 Thomas Reiberger,1,3– 5 Christian Müller,1,2 Michael Trauner,1,4 Matthias Pinter1,2,4 1Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; 2Liver Cancer (HCC) Study Group Vienna, Medical University of Vienna, Vienna, Austria; 3Vienna Hepatic Hemodynamic Laboratory, Medical University of Vienna, Vienna, Austria; 4Rare Liver Disease (RALID) Centre of the ERN RARE-LIVER, Medical University of Vienna, Vienna, Austria; 5Christian Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria*These authors contributed equally to this workCorrespondence: Matthias PinterDivision of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, AustriaTel +43 1 40400 47440Fax +43 1 40400 47350Email matthias.pinter@meduniwien.ac.atBackground: Antibiotic treatment (ABT) affects the outcome of cancer patients treated with immune checkpoint inhibitors (ICIs) and chemotherapy, possibly by altering the gut microbiome. We investigated the impact of ABT on overall survival (OS) and progression-free survival (PFS) in patients with advanced HCC treated with sorafenib.Methods: HCC patients treated with sorafenib between 05/2006 and 03/2020 at the Medical University of Vienna were retrospectively analyzed. ABT was defined as antibiotic use within 30 days prior to or after sorafenib initiation.Results: Of 206 patients, the majority was male (n=171, 83%) with a mean age of 66± 9.6 years. Half of patients (n=94, 46%) had impaired liver function (Child-Pugh stage B). Median time of follow-up was 10.8 (95% CI: 9.2– 12.3) months. ABT was administered in 23 (11%) patients due to different types of proven or clinically suspected bacterial infections (n=17, 74%) and hepatic encephalopathy (n=6, 26%). The median duration of ABT was 14 (IQR: 12– 30) days. Penicillin (n=13, 57%), followed by rifaximin (n=6, 26%), fluoroquinolones (n=3, 13%), and cephalosporins (n=1, 4%), was administered in the ABT group. The ABT group had a significantly shorter median OS (4.7 (95% CI: 3.2– 6.1) months vs 11.4 (95% CI: 9.9– 12.9) months, p=0.012), which was confirmed in multivariable analysis (HR: 1.91 (95% CI: 1.1– 3.2), p=0.014). Similarly, PFS trended to be shorter in the ABT group (3.5 (95% CI: 1.6– 5.4) months vs 4.8 (95% CI: 3.9– 5.7) months, p=0.099). None of the 10 patients with complete or partial response was found in the ABT group.Conclusion: ABT was independently associated with worse outcomes in sorafenib-treated HCC patients. Prospective studies are needed to elucidate the underlying mechanism.Keywords: antibiotics, hepatocellular carcinoma, sorafenib, targeted therapy |
| format |
article |
| author |
Pomej K Balcar L Scheiner B Semmler G Meischl T Mandorfer M Reiberger T Müller C Trauner M Pinter M |
| author_facet |
Pomej K Balcar L Scheiner B Semmler G Meischl T Mandorfer M Reiberger T Müller C Trauner M Pinter M |
| author_sort |
Pomej K |
| title |
Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib |
| title_short |
Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib |
| title_full |
Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib |
| title_fullStr |
Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib |
| title_full_unstemmed |
Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib |
| title_sort |
antibiotic therapy is associated with worse outcome in patients with hepatocellular carcinoma treated with sorafenib |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/34e445ecb8884eeb86cb8d444efa3051 |
| work_keys_str_mv |
AT pomejk antibiotictherapyisassociatedwithworseoutcomeinpatientswithhepatocellularcarcinomatreatedwithsorafenib AT balcarl antibiotictherapyisassociatedwithworseoutcomeinpatientswithhepatocellularcarcinomatreatedwithsorafenib AT scheinerb antibiotictherapyisassociatedwithworseoutcomeinpatientswithhepatocellularcarcinomatreatedwithsorafenib AT semmlerg antibiotictherapyisassociatedwithworseoutcomeinpatientswithhepatocellularcarcinomatreatedwithsorafenib AT meischlt antibiotictherapyisassociatedwithworseoutcomeinpatientswithhepatocellularcarcinomatreatedwithsorafenib AT mandorferm antibiotictherapyisassociatedwithworseoutcomeinpatientswithhepatocellularcarcinomatreatedwithsorafenib AT reibergert antibiotictherapyisassociatedwithworseoutcomeinpatientswithhepatocellularcarcinomatreatedwithsorafenib AT mullerc antibiotictherapyisassociatedwithworseoutcomeinpatientswithhepatocellularcarcinomatreatedwithsorafenib AT traunerm antibiotictherapyisassociatedwithworseoutcomeinpatientswithhepatocellularcarcinomatreatedwithsorafenib AT pinterm antibiotictherapyisassociatedwithworseoutcomeinpatientswithhepatocellularcarcinomatreatedwithsorafenib |
| _version_ |
1718406314814603264 |